A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma is a research paper published in Cancer Discovery (2025). On theSindex it has a DataRank of 0.425. It has been cited 16 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NWO Dutch Research Council
Grant: Rubicon Fellowship 452182318
MSKCC Cancer Center Support Grant
Grant: P30CA008748
Cancer Research Institute
Grant: #3441
National Cancer Institute
Grant: 1F31CA271770-01
National Cancer Institute
Grant: K99CA279782
NCI NIH HHS
Grant: F31 CA271770
Break Through Cancer (BTC)
Helen Hay Whitney Foundation
Mark Foundation For Cancer Research
Break Through Cancer
Helen Hay Whitney Foundation (HHWF)
Mark Foundation For Cancer Research (The Mark Foundation for Cancer Research)
Revolution Medicines
Revolution Medicines (REVOLUTION Medicines Inc)
FWCI
7.73
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords